Daniel Soffel

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study

H. Lipp, C. Garbe, B. Klumpp, 2017, Cancer Immunology, Immunotherapy.

Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy

C. Garbe, G. Pawelec, P. Terheyden, 2021, Journal for ImmunoTherapy of Cancer.

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade

C. Garbe, G. Pawelec, P. Terheyden, 2019, PloS one.